David R Coghill1, Sarah Seth2, Sara Pedroso3, Tatiana Usala4, John Currie5, Antonella Gagliano6. 1. Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital. Electronic address: d.r.coghill@dundee.ac.uk. 2. Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital; National Health Service Tayside, Child and Adolescent Mental Health Service, Dundee, United Kingdom. 3. Department of Child and Adolescent Psychiatry, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. 4. UMEE (Unità Multidisciplinare per l'età evolutiva) ASUR , Jesi. 5. Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital. 6. Department of Pediatric Science, University of Messina, Policlinico Universitario G. Martino, Messina, Italy.
Abstract
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is associated with a broad range of neuropsychological impairments. The relationship between these neuropsychological deficits and the defining symptoms of ADHD seems more complex than originally thought. Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but its impact on cognition is less clearly understood. METHODS: With a common systematic search strategy and a rigorous coding and data extraction strategy across domains, we searched electronic databases to identify published placebo controlled trials that compared MPH and placebo on executive and nonexecutive memory, reaction time, reaction time variability and response inhibition in children and adolescents (5-18 years) with a formal diagnosis of ADHD. RESULTS: Sixty studies were included in the review, of which 36 contained sufficient data for meta-analysis. Methylphenidate was superior to placebo in all five meta-analyses: executive memory, standardized mean difference (SMD) .26, 95% confidence interval (CI): -.39 to -.13; non-executive memory, SMD .60, 95% CI: -.79 to -.41; reaction time, SMD .24, 95% CI: -.33 to -.15; reaction time variability, SMD .62, 95% CI: -.90 to -.34; response inhibition, SMD .41, 95% CI: -.55 to -.27. CONCLUSIONS: These data support the potentially important effects of MPH on various aspects of cognition known to be associated with ADHD. Consideration should be given to adding cognitive outcomes to the assessment of treatment outcome in ADHD, considering the complexity of the relationship between ADHD symptoms and cognition.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) is associated with a broad range of neuropsychological impairments. The relationship between these neuropsychological deficits and the defining symptoms of ADHD seems more complex than originally thought. Methylphenidate (MPH) is an effective treatment for ADHD symptoms, but its impact on cognition is less clearly understood. METHODS: With a common systematic search strategy and a rigorous coding and data extraction strategy across domains, we searched electronic databases to identify published placebo controlled trials that compared MPH and placebo on executive and nonexecutive memory, reaction time, reaction time variability and response inhibition in children and adolescents (5-18 years) with a formal diagnosis of ADHD. RESULTS: Sixty studies were included in the review, of which 36 contained sufficient data for meta-analysis. Methylphenidate was superior to placebo in all five meta-analyses: executive memory, standardized mean difference (SMD) .26, 95% confidence interval (CI): -.39 to -.13; non-executive memory, SMD .60, 95% CI: -.79 to -.41; reaction time, SMD .24, 95% CI: -.33 to -.15; reaction time variability, SMD .62, 95% CI: -.90 to -.34; response inhibition, SMD .41, 95% CI: -.55 to -.27. CONCLUSIONS: These data support the potentially important effects of MPH on various aspects of cognition known to be associated with ADHD. Consideration should be given to adding cognitive outcomes to the assessment of treatment outcome in ADHD, considering the complexity of the relationship between ADHD symptoms and cognition.
Authors: Viviana A Peskin; Anna Ordóñez; R Scott Mackin; Kevin Delucchi; Silvia Monge; James J McGough; Denise A Chavira; Monica Berrocal; Erika Cheung; Eduardo Fournier; Judith A Badner; Luis Diego Herrera; Carol A Mathews Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2015-03-31 Impact factor: 3.568
Authors: Merideth A Addicott; Julia C Schechter; Jeffrey J Sapyta; James P Selig; Scott H Kollins; Margaret D Weiss Journal: Pharmacol Biochem Behav Date: 2019-06-18 Impact factor: 3.533
Authors: Jasmin E Guevara; Sarah Gilbert; Kyle W Murdock; Raymond P Stowe; Christopher P Fagundes Journal: Stress Health Date: 2019-07-11 Impact factor: 3.519
Authors: David Pagliaccio; Jillian Lee Wiggins; Nancy E Adleman; Alexa Curhan; Susan Zhang; Kenneth E Towbin; Melissa A Brotman; Daniel S Pine; Ellen Leibenluft Journal: J Am Acad Child Adolesc Psychiatry Date: 2017-03-07 Impact factor: 8.829
Authors: Robert M Bilder; Sandra K Loo; James J McGough; Fiona Whelan; Gerhard Hellemann; Catherine Sugar; Melissa Del'Homme; Alexandra Sturm; Jennifer Cowen; Grant Hanada; James T McCracken Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-06-07 Impact factor: 8.829